Skip to main content
OpenTrials
Completed

NCT Number: NCT03383718

DSE vs. FFR in SCAD and BYSTANDER Lesions

Enrollment:

* Patients with stable coronary artery disease (SCAD) and moderate coronary artery stenoses (30-70 %) * Patients with acute myocardial infarction and moderate stenosis of non-culprit arteries (NCL; BYSTANDER LESION)

Aims:

* To assess the diagnostic accuracy of dobutamine stress echocardiography (DSE) and invasive fractional flow reserve (FFR) measurement * To assess the prognostic impact of reclassification by a mismatching negative test

Hypothesis:

* DSE and FFR have similar prognostic value in both clinical settings (SCAD and NCL) * Considering the strong negative predictive value of both DSE and FFR, one negative test is sufficiently enough to defer revascularisation, even in the case of mismatch

Completed

Looking for future studies?

Notify Me

Key information

About this study

Easy accessibility made fractional flow reserve (FFR) a widely accepted method to evaluate myocardial ischaemia in patients with moderate coronary artery stenosis, although the prognostic value for "hard" endpoints such as myocardial infarction and cardiovascular death is equivocal.

Dobutamine stress echocardiography (DSE) is a useful and safe non-invasive functional test for myocardial ichaemia evaluation. There are robust data confirming the prognostic value of DSE regarding the same "hard" endpoints.

In patients with SCAD there are clear recommendations in the recent guidelines both for DSE guided or FFR guided revascularization but the data about prognosis is limited, especially in the case of FFR guidance. The outcome is also equivocal if there is a difference between the invasive and non-invasive test result.

In patients with acute myocardial infarction, more than 50% of patients have multivessel disease. There are clear recommendations for the management of infarct related artery, however controversy still exists for the management of angiographically moderate NCLs.

In DSE vs. FFR prospective trial, the Investigators plan to perform both the DSE and FFR tests in the above mentioned clinical settings, to investigate the correlation between them. The causes of differences between them would be investigated as well as the prognostic impact of reclassification by a second test (either DSE or FFR).

If both tests are positive, revascularisation is planned to be performed (PCI Group). In cases of either double negative or mismatching tests, optimal medical therapy will be chosen (OMT Group) with clinical follow up of at least 2 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age>18 years
  • Moderate Coronary Stenosis (30-70 %)
  • Stable coronary artery disease or patients with acute myocardial infarction and at least one moderate non-culprit vessel stenosis

Exclusion criteria

  • Left Main Coronary artery stenosis
  • Age>80 years
  • Known non-cardiovascular disease with poor prognosis
  • Patients for whom coronary angiography or stress echocardiography is contraindicated per institutional standard of care (e.g. History of severe and/or anaphylactic contrast reaction)
  • Inability to provide informed consent;
  • Inability to cooperate with the investigation
  • Pregnancy

Treatment and study plan

Revascularisation

Procedure

Percutaneous coronary intervention or coronary artery bypass surgery

Other names: PCI or CABG

Optimal Medical Treatment/OMT

Other

Standard of care in stable coronary artery disease or after acute myocardial infarction.

Primary outcomes

  1. Acute Myocardial Infarction

    Time frame: From baseline to at least 2 years

    Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one value above the 99th percentile upper reference limit (URL) and with at least one of the following: Symptoms of ischaemia. New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB).

    Development of pathological Q waves in the ECG. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

    Identification of an intracoronary thrombus by angiography or autopsy

  2. Target Vessel Revascularisation

    Time frame: From baseline to at least 2 years

    The Investigated Vessel need Revascularisation because of at least Canadian Cardiology Society Angina Class III

  3. Cardiovascular Death

    Time frame: From baseline to at least 2 years

    Death occurs due to Cardiovascular cause

Secondary outcomes

  1. Angina

    Time frame: From baseline to at least 2 years

    Rehospitalisation due to Angina

  2. Heart failure

    Time frame: From baseline to at least 2 years

    Rehospitalisation due to Heart Failure

  3. Non-Cardiac Death

    Time frame: From baseline to at least 2 years

    Death occurs due to Non-Cardiovascular cause

  4. Non-Target Vessel Revascularisation

    Time frame: From baseline to at least 2 years

    The Non-Investigated Vessel need Revascularisation

Sponsors and collaborators

Lead sponsor

Bajcsy-Zsilinszky Hospital

Other

Collaborators

  • Semmelweis University Heart and Vascular Center

Registry information

Official study title

Comparison of Dobutamine Stress Echocardiography and Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease: Stable and Non-culprit Lesions Investigation

Acronym: DSE-vs-FFR

Important dates

Study start
2014
Primary completion
2017
Study completion
2019
First posted
Dec 26, 2017
Registry last updated
Jan 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.